Literature DB >> 16257138

Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenophine substitution.

Claude Lejeune1, Laurence Simmat-Durand, Laurent Gourarier, Sandrine Aubisson.   

Abstract

Specialized prenatal care and substitution programs improve the perinatal prognoses of pregnant drug-abusers and their infants. Although methadone is well documented, little is known about high-dose buprenorphine (HDB). This prospective, multicenter (n = 35) observational study included 259 women on maintenance during pregnancy: 39% on methadone and 61% on HDB. Major findings were: 46% of them received good prenatal care; 62% had peridural analgesia; 12.3% delivered prematurely (<37 weeks); mean gestational age, 38.6 weeks; mean birth weight, 2822g. Three-quarters of the newborns developed neonatal abstinence syndrome (NAS) beginning at a mean age of 40h, with the mean maximum Lipsitz score of 9.1 at 72 h; half of them were treated, mainly with morphine hydrochloride. No baby died. Newborns were discharged with their mothers (96%) or placed in foster care (4%). Comparing methadone with HDB, respectively, mean age at the maximum Lipsitz score was 81 h versus 66 h (P = 0.066). The perinatal medical and social prognoses for these 259 drug addicts and their infants appeared to be improved by specialized prenatal care and was similar for methadone or BHD substitution during pregnancy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16257138     DOI: 10.1016/j.drugalcdep.2005.10.001

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  62 in total

Review 1.  Pharmacological Management of Opioid Use Disorder in Pregnant Women.

Authors:  Christine M Wilder; Theresa Winhusen
Journal:  CNS Drugs       Date:  2015-08       Impact factor: 5.749

2.  Validation and application of a method for the determination of buprenorphine, norbuprenorphine, and their glucuronide conjugates in human meconium.

Authors:  Sherri L Kacinko; Diaa M Shakleya; Marilyn A Huestis
Journal:  Anal Chem       Date:  2007-11-29       Impact factor: 6.986

3.  Prenatally buprenorphine-exposed children: health to 3 years of age.

Authors:  Kaisa Kivistö; Sarimari Tupola; Satu Kivitie-Kallio
Journal:  Eur J Pediatr       Date:  2015-05-24       Impact factor: 3.183

Review 4.  The treatment of alcohol and opioid dependence in pregnant women.

Authors:  Annemarie Heberlein; Lorenzo Leggio; Dirk Stichtenoth; Thomas Hillemacher
Journal:  Curr Opin Psychiatry       Date:  2012-11       Impact factor: 4.741

5.  Maternal buprenorphine treatment and infant outcome.

Authors:  Lauren M Jansson; Martha L Velez; Krystle McConnell; Nancy Spencer; Michelle Tuten; Hendree Jones; Rebeca Rios; Van L King; Neeraj Gandotra; Lorraine Millio; Janet A DiPietro
Journal:  Drug Alcohol Depend       Date:  2017-08-31       Impact factor: 4.492

6.  Characteristics of opioid-using pregnant women who accept or refuse participation in a clinical trial: screening results from the MOTHER study.

Authors:  Susan M Stine; Sarah H Heil; Karol Kaltenbach; Peter R Martin; Mara G Coyle; Gabriele Fischer; Amelia M Arria; Peter Selby; Hendree E Jones
Journal:  Am J Drug Alcohol Abuse       Date:  2009       Impact factor: 3.829

7.  Opioid addiction and pregnancy: perinatal exposure to buprenorphine affects myelination in the developing brain.

Authors:  Emilse S Sanchez; John W Bigbee; Wambura Fobbs; Susan E Robinson; Carmen Sato-Bigbee
Journal:  Glia       Date:  2008-07       Impact factor: 7.452

8.  Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy.

Authors:  Hendrée E Jones; Erin Dengler; Anna Garrison; Kevin E O'Grady; Carl Seashore; Evette Horton; Kim Andringa; Lauren M Jansson; John Thorp
Journal:  Drug Alcohol Depend       Date:  2013-11-16       Impact factor: 4.492

9.  Confirmatory analysis of buprenorphine, norbuprenorphine, and glucuronide metabolites in plasma by LCMSMS. Application to umbilical cord plasma from buprenorphine-maintained pregnant women.

Authors:  Marta Concheiro; Hendreé Jones; Rolley E Johnson; Diaa M Shakleya; Marilyn A Huestis
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2010-01-01       Impact factor: 3.205

10.  The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data.

Authors:  W O Farid; S A Dunlop; R J Tait; G K Hulse
Journal:  Curr Neuropharmacol       Date:  2008-06       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.